Several institutional investors and hedge funds have added or reduced stakes in Eli Lilly and Company. Capital Planning LLC bought shares valued at $262,000 in the first quarter. CHURCHILL MANAGEMENT Corp purchased shares worth $6,916,000 in the 1st quarter. M&G Plc invested $8,896,000 in the 1st quarter. HighPoint Advisor Group LLC added $9,878,000 in the 4th quarter and Leo Wealth LLC invested $3,355,000 in the 4th quarter. Hedge funds and institutional investors own 82.53% of the company’s stock.
Insiders Place Their Bets
Major shareholder Lilly Endowment Inc sold 8,848 shares of the company’s stock on Wednesday, July 3rd for a total of $8,098,662.88. The insider now holds approximately $89,059,454,309.32 worth of shares. Insiders sold 364,810 shares in the last ninety days, with 0.13% currently owned by insiders.
Analyst Ratings Changes
Several brokerages have given LLY buy ratings. Truist Financial reiterated a “buy” rating with a target price of $1,000.00 on June 25th. Citigroup initiated coverage with a “buy” rating and a target price of $1,060.00 on September 13th. Deutsche Bank Aktiengesellschaft upgraded LLY to a “buy” rating with a new target price of $1,025.00 on August 12th. Berenberg Bank raised the target price to $1,050.00 and gave a “buy” rating on August 14th. Barclays also raised their target price to $1,025.00 and rated the company as “overweight” on July 10th. According to MarketBeat, the average rating for LLY is “Moderate Buy” with an average price target of $977.35.
Check Out Our Latest Analysis on LLY
Eli Lilly and Company Stock Performance
NYSE LLY opened at $885.56 on Tuesday. The company has a market cap of $841.64 billion, a P/E ratio of 130.42, a P/E/G ratio of 2.78, and a beta of 0.42. The business’s 50-day moving average price is $896.50 and its 200-day moving average price is $844.99. LLY has a 52-week low of $516.57 and a 52-week high of $972.53.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last reported $3.92 EPS for the quarter ending on August 8th, surpassing the consensus estimate of $2.64 by $1.28. The company had a revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. LLY has a return on equity of 67.52% and a net margin of 18.86%. Analysts anticipate an EPS of 16.49 for the current year.
Eli Lilly and Company Company Profile
Eli Lilly and Company is a global pharmaceutical company, offering products for diabetes, type 2 diabetes, and obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- Investing In Automotive Stocks
- Why Q2 Holdings Stock Could Be Your Next Big Buy
- Pros And Cons Of Monthly Dividend Stocks
- October’s Big Winners: Top 5 Stocks to Keep on Your Radar
- How Technical Indicators Can Help You Find Oversold Stocks
- Instacart Is Revolutionizing Groceries: Why It’s Time to Invest
Receive News & Ratings for Eli Lilly and Company Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Eli Lilly and Company and related companies with MarketBeat.com’s FREE daily email newsletter.
